Tackling the Serious Global Challenges in Infectious Disease

Appili was created to deliver innovative drug development programs for unmet patient needs across a broad spectrum of infectious diseases

Appili Therapeutics Infectiou Disease Drug Development Program

Advancing infectious disease drug development programs to provide solutions to patients, doctors, and society.

Leadership team skilled in advancing programs with upside potential

Active partnering and in-licensing efforts to expand clinical programs and accelerate commercialization

Appili Therapeutics: Innovation Across a Broad Spectrum of Anti-Infectives


Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer
Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™